| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910483536303321 |
|
|
Titolo |
Alternative medicine interventions for COVID-19 / / Muhammad Zia-Ul-Haq [and three others] editors |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2021] |
|
©2021 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (291 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
COVID-19 (Disease) - Alternative treatment |
COVID-19 |
Medicina alternativa |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Contents -- About the Editors -- Chapter 1: Introduction to COVID-19 -- Introduction -- Origin of COVID -- Emergence and Epidemiology -- Human-Animal Interaction as Risk Factor -- Best Suitable Animal Model -- COVID and Animal Welfare -- Molecular Differences Between Different Animal Species -- Vaccines for COVID from Animals -- Conclusion -- References -- Chapter 2: Medicinal Plants as COVID-19 Remedy -- Introduction -- Existing Plants with Potential Therapeutic Applications for Coronavirus Family (SARS-CoV) -- Plants as Specific Inhibitors of HCoV Target Proteins -- Bupleurum Species -- Artemisia annua L. -- Isatis indigotica Fortune ex Lindl. -- Alcea digitata (Boiss.) Alef. -- Lycoris radiata (L'Hér.) Herb. -- Pyrrosia lingua (Thunb.) Farw. -- Houttuynia cordata Thunb. -- Torreya nucifera L. -- Lindera aggregata (Sims) Kosterm. -- Rheum palmatum L. -- Cerasus avium (L.) Moench. -- Polygonum multiflorum Thunb. -- Citrus aurantium L. -- Rubia tinctorum L. -- Onopordum acanthium L. -- Quercus infectoria G. Olivier -- Crataegus microphylla C. Koch -- Berberis integerrima Bunge -- Alnus japonica (Thunb.) Steud. -- Paulownia tomentosa (Thunb.) Steud. -- Psoralea corylifolia L. -- Tribulus terrestris L. -- Medicinal Plants as Potential Source of Natural |
|
|
|
|
|
|
|
|
|
Antiviral Agents Against COVID -19 -- Allium Sativum (Garlic) -- Azadirachta indica (Neem) -- Curcuma domestica (Turmeric, Haldi) -- Echinacea purpurea L. (Echinacea) -- Foeniculum vulgare Mill. (Fennel) -- Glycyrrhiza glabra (Licorice) -- Melissa officinalis L. (Lemon Balm) -- Mentha piperita L. (Peppermint) -- Nigella sativa L. (Black Seeds) -- Origanum vulgare L. (Oregano) -- Ocimum bacilicum L. (Basil) -- Rosmarinus officinalis L. (Rosemary) -- Salvia officinalis L. (Sage) -- Senna alexandrina Mill. (Senna Makki) -- Zingiber officinale Rosc. (Ginger) -- Limitations. |
Conclusions -- References -- Chapter 3: Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2 -- Introduction -- Traditional Chinese Medical Practices -- Laws for TCM Formulation -- Antiviral Potential of Plant Metabolites -- Structure of SARS-CoV-2 -- Relevance of SARS-CoV with SARS-CoV-2 -- Entry of SARS-CoV vs. SARS-CoV-2 into Host Cell -- TCM and SARS-CoV -- TCM and SARS-CoV-2 (COVID-19) -- Most Practiced Herbs in Formulations Against COVID-19 -- Utilization Frequency of Herbs in the Formulation of (COVID-19) Decoctions -- Approved/Proposed Decoctions with Successful Clinical Trials -- Qingfei Paidu Decoction (QFPD) (Approved) -- Huashi Baidu Decoction (HBD) (Approved) -- Xiaochaihu Decoction (XCHD) -- Xuanfei Baidu Decoction (XFBD) (Approved) -- Jinhua Qinggan (JQ) (Approved) -- Huoxiang Zhengqi (HZ) Capsule -- Lianhua Qingwen (LQ) -- Xuebijing Injection (XbI) (Approved) -- Reduning Injection (RdI) -- Shufeng Jiedu Capsule (SFJC) -- Ma Xing Shi Gan Decoction (MXSGD) (Approved) -- Yin Qiao San (YQS) -- Yupingfeng San (YPFS) -- Therapeutic Logic of TCM as COVID-19 Inhibitor -- Mechanism of Direct Inhibition -- TCM Targeting ACE2 -- TCM Targeting Protease -- TCM Directly Targeting DNA Via Intercalation -- TCM Directly Targeting DNA via JAK-STAT Signaling Pathway -- TCM Targeting sEH -- Targeting VEGF -- Targeting DPP4 -- Targeting JUN -- Targeting EGFR -- Targeting IL1B -- Mechanism of Indirect Mechanisms -- Anti-inflammation and Immune Regulation to Avoid Cytokine Storm -- TCM Protect Organ Damage in COVID-19 Patients -- Regulation of Renin-Angiotensin-Aldosterone System (RAAS) and Potential TCM Targets -- Cytokine-Mediated Positive and Negative Immunity -- TCM Targeting MAPK (Cytokine) -- TCM Targeting Platinum Drug Resistance (Cytokine) -- TCM Targeting Tyrosine Kinase Resistance (Cytokine). |
TCM Targeting Interleukins (ILs) (Cytokine) -- TCM Targeting TNF (Cytokines) -- TCM Targeting Lymphocyte-Mediated Adaptive Immune System -- Regulation of Apoptosis and Potential TCM Targets -- TCM Targeting BCL Proteins -- TCM Targeting CASP -- 7TCM Targeting Akt or Protein Kinase B (PKB) -- Regulation of NF-κB Pathway and Potential TCM Targets -- TCM Targeting TP53 -- TCM Targeting ICAM1 -- TCM Targeting RELA -- Regulation of Arachidonic Acid Metabolism and Potential TCM Targets -- TCM Targeting cPLA2α of Arachidonic Acid Metabolism -- TCM Targeting Cyclooxygenase-2 of Arachidonic Acid Metabolism -- TCM Targeting LOX of Arachidonic Acid Metabolism -- TCM Targeting Cytochrome P450 -- TCM Targeting Leukotrienes (LTs) -- TCM Targeting CALM -- TCM Targeting HIF-1 Signaling Pathways -- TCM Targeting Endocrine Resistance -- TCM Targeting FOS -- TCM Targeting PTGS2 -- Regulation of Polyamine Metabolism and Potential TCM Targets -- TCM Targeting NOS2 and AOC1 -- TCM Targeting CCL2 -- Meta-analysis -- TCM from Chinese Combat Zone to World Combat Zone -- Shortcomings of Antiviral Medicine on COVID-19 -- Conclusions -- References -- Chapter 4: Plant-Based Natural Products: Potential Anti-COVID-19 Agents -- Introduction -- Antiviral Mechanistic Aspects of Phytochemicals -- Mechanism -- Plant Selection for Antiviral Screening -- Different Classes of Phytochemicals |
|
|
|
|
|
|
|
|
as Antiviral Agents -- Alkaloids -- Flavonoids -- Classification of Flavonoids -- Chalcones -- Dihydrochalcones -- Flavones -- Flavonones -- Dihydroflavonols -- Flavonol -- Isoflavonoids -- Isoflavones -- Isoflavanones -- Neoflavonoids -- Terpenoids -- Tannins -- Vitamins -- Chromones and Coumarins -- Organosulfur Compounds -- Selenium Compounds -- Miscellaneous Antiviral Phytochemicals -- Curcumin and Its Derivative -- Chlorophyllin -- Gingerols -- Chitin and Chitosan -- Anthraquinone -- Conclusion. |
References -- Chapter 5: Foods as First Defense Against COVID-19 -- Introduction -- Role of Nutrition and Diet in Prevention and Management of COVID-19 -- Prioritizing Nutrition Interventions During COVID-19 -- Grains -- Vegetables and Fruits -- Nuts -- Legumes -- Meat -- Milk and Milk Products -- Herbs -- Role of Vitamins in COVID-19 -- Vitamin A -- Vitamin B -- Vitamin C -- Vitamin D -- Vitamin E -- Role of Minerals in COVID-19 -- Iron -- Selenium -- Zinc -- Magnesium -- Role of Omega-3 Polyunsaturated Fatty Acids -- Nutrients for Immune System and Resilience in COVID-19 -- Nutrition in Lowering Stress and Depression in COVID-19 -- Food Choices for Diabetic Patients During COVID-19 -- Food Choices for Cardiovascular Patients During COVID-19 -- Food Choices for Cancer Patients During COVID-19 -- Food Choices for Patients with Digestive Disorders During COVID-19 -- Food Choices for Pulmonary Disease Patients During COVID-19 -- Malnutrition May Exacerbate COVID-19 -- Nutrition and Post-COVID Recovery -- Future Perspectives -- Conclusion -- References -- Chapter 6: Drugs for the Treatment of COVID-19 -- Introduction -- Dexamethasone -- Chloroquine -- Remdesivir -- Angiotensin-Converting Enzyme Inhibitors -- Spike Protein Inhibitors -- Conclusions -- References -- Chapter 7: COVID-19 Pandemic and Vaccines -- Introduction -- COVID-19 Vaccines: A Need of Time -- Coronavirus Vaccine Development: Challenges of the Past -- Vaccine Development Strategies -- Nucleic Acid Vaccines -- Protein Subunit Vaccines -- Inactivated or Live-Attenuated Virus Vaccines -- Virus Vector-Based Vaccines -- Repurposed Vaccines for COVID-19 and Off-Target Effects of Other Vaccines -- Plant-Based Vaccines -- Animal Models for SARS-CoV-2 Studies -- Cell Culture Systems for SARS-CoV-2 Studies -- Clinical and Immunological Endpoints -- Vaccine Development Landscape. |
Global and Equitable Distribution of Vaccines -- Vaccine Developers and Geographical Distribution -- Conclusions -- References -- Chapter 8: Updates in Vaccine Development Against COVID-19 -- Introduction -- Sinovac Biotech, China -- Conclusions -- Bibliography -- Chapter 9: COVID-19: Recent Developments in Therapeutic Approaches -- Introduction -- Morphology of SARS-CoV-2 -- Genome Organization of SARS-CoV-2 -- Replication of SARS-CoV-2 -- Transmission and Pathogenesis of SARS-CoV-2 -- Clinical Characterization of SARS-CoV-2 -- Clinical and Laboratory Diagnosis of SARS-CoV-2 -- Therapeutic Options for the Treatment of COVID-19 -- Antivirals or Immunomodulatory Drugs for COVID-19 -- Vaccine for COVID-19 -- Plasma/Serotherapy for COVID-19 -- Alternative Therapies -- Anticoagulant Therapy -- Glucocorticoids (GC) -- Stem Cell-Based Therapy -- ACE-2-Mediated Therapies -- CRISPR/Cas System -- Conclusion -- References -- Index. |
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910798518603321 |
|
|
Autore |
Terrace Vincent |
|
|
Titolo |
Internet children's television series, 1997-2015 / / Vincent Terrace |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Jefferson, North Carolina : , : McFarland & Company, Inc., Publishers, , 2016 |
|
©2016 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (199 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Internet television |
Children's television programs |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Sommario/riassunto |
|
"A one-of-a-kind book that chronicles television produced for the Internet. It, along with its four prior volumes is the only printed source that covers the Internet. The reader will find story lines, casts and credits, web sites, episode listings and year of production. This edition covers 573 children's series"-- |
|
|
|
|
|
|
|
| |